Small EPO-Derived Peptide Boosts Heart Health and Extends Healthspan

While Erythropoietin (EPO) is primarily known for stimulating red blood cell production, it also possesses significant tissue-protective and anti-inflammatory properties. However, the therapeutic use of full-length EPO is often hindered by its hematopoietic (red blood cell-producing) side effects, which can increase risks like thrombosis. There remains a critical knowledge gap in developing targeted therapies that can harness EPO's beneficial non-hematopoietic effects, particularly for mitigating age-associated cardiac decline, without inducing undesirable systemic hematopoietic responses.

The study revealed compelling evidence that treatment with the EPO-SP significantly improved cardiac health and extended healthspan in aged mice. Specifically, treated animals showed a remarkable 35% reduction in key cardiac inflammatory markers (e.g., IL-6, TNF-alpha) compared to control mice (p<0.01). Furthermore, heart function was substantially preserved; ejection fraction improved by 15% (p<0.001) in the treated group, and cardiac fibrosis was attenuated by 20% (p<0.05). The most striking finding was a significant 10% increase in the median healthspan of EPO-SP treated mice, alongside a 25% improvement in overall physical activity scores, demonstrating potent anti-aging and cardioprotective effects without stimulating red blood cell production. These benefits were observed consistently across multiple physiological parameters, suggesting a broad impact on age-related decline.